MTNB stock forecast, quote, news & analysis
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products... Show more
Why Matinas BioPharma (MTNB) Stock Is Down -41% in the Last 30 Days
Key Takeaways
- MTNB shares traded near $1.51 in late October 2026, down roughly 41% from the September 30, 2026 closing price of $2.55.
- The decline followed a 1-for-15 reverse stock split effective September 28, 2026, a move that has been accompanied by elevated volatility and thin liquidity.
- A sharp single-session drop of about 30% on October 19, 2026 accelerated the slide as post-split selling pressure persisted.
- Shares remain under pressure as investors weigh the pending business combination with GH Power and the planned sale of the MAT2203 and LNC platform assets to Azurity Pharmaceuticals.
- NYSE American continued-listing compliance concerns and ongoing operating losses continue to weigh on sentiment.
- Get additional context on valuation and estimates by exploring the Price Targets, Earnings, and Forecast pages for this ticker.
- Discover signal-driven trading ideas by exploring Trending AI Robots.
Matinas BioPharma (MTNB) Company Overview and Market Position
Matinas BioPharma Holdings, Inc. is a Bedminster, New Jersey-based clinical-stage biopharmaceutical company built around its proprietary lipid nanocrystal (LNC) platform for the oral, intracellular delivery of small molecules and other therapeutics. Its lead candidate, MAT2203 (oral amphotericin B), is an antifungal treatment developed for invasive fungal infections, having completed a Phase 2 study in cryptococcal meningitis.
In 2026, the company underwent a strategic pivot. It announced a definitive business combination agreement with GH Power Inc., a Toronto-based clean energy and critical minerals company, and separately agreed to sell its LNC platform and MAT2203 assets to Azurity Pharmaceuticals. As a result, investors now follow MTNB primarily for the progress and closing of these corporate transactions rather than for near-term drug-development milestones.
Matinas BioPharma (MTNB) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, MTNB fell from a closing price of $2.55 on September 30, 2026, to approximately $1.51, a decline of about 41%. The move was punctuated by a single-session decline of roughly 30% on October 19, when the stock dropped from $2.37 to $1.66.
The longer-term trend is similarly negative. Roughly three months earlier, in late July 2026, the stock was trading near $4.76. Since then, MTNB has declined approximately 68%, reflecting a sustained multi-month selloff that began after an initial spike around the July 2026 merger announcement.
What Drove MTNB Stock Price in the Last 30 Days
The 30-day decline occurred against a backdrop of post-reverse-split volatility. The 1-for-15 reverse stock split that took effect September 28, 2026, was intended to raise the per-share price and support the company's NYSE American listing, but it also reset the share structure at a time of low liquidity, leaving the stock vulnerable to outsized single-day moves.
The sharp October 19 drop occurred amid thin trading volumes and persistent post-split selling pressure, with no single company-issued catalyst to explain the move. Broader investor concerns have centered on dilution risk, the financing requirements tied to the pending GH Power combination, and uncertainty over whether the transaction will close on its stated timeline. NYSE American non-compliance notices related to stockholders' equity shortfalls have added to the overhang.
What Drove MTNB Stock Performance Over the Last Quarter
The quarterly trend reflects the transition from a biopharmaceutical developer to a vehicle for a clean-energy business combination. After the July 13, 2026 announcement of the GH Power agreement, MTNB initially spiked before steadily giving back gains as the market digested the transaction's structure.
Under the terms, existing Matinas equityholders are expected to own approximately 9% of the combined company, GH Power International, with each Matinas share converting into 0.1 of a GHP International share. The separate agreement to sell the LNC platform and MAT2203 to Azurity Pharmaceuticals for $4 million upfront plus up to $17.5 million in milestone payments and royalties further reframed the investment thesis. Combined with the reverse split, continued net losses, and exchange-compliance uncertainty, these structural changes contributed to the multi-month decline.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of algorithmic trading strategies. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, allowing traders to evaluate approaches aligned with different objectives and risk tolerances. Because the selection is continuously refreshed based on performance and relevance, the page offers a practical starting point for those interested in systematic, signal-driven trading tools. Visitors can browse the featured robots to see which strategies are currently attracting attention.
MTNB Stock Forecast Drivers: What Investors Should Watch Next
The most significant upcoming factors for MTNB revolve around the pending corporate transactions. Investors will monitor whether the GH Power business combination satisfies its closing conditions, including stockholder and regulatory approvals, SEC registration effectiveness, NYSE American listing approval, and GH Power's minimum $15 million financing requirement. The agreement also contains termination rights exercisable if the closing has not occurred by December 31, 2026.
Other items to watch include completion of the Azurity asset sale and any related milestone or royalty developments, progress toward regaining NYSE American continued-listing compliance under the plan period extending to October 2, 2027, and the company's quarterly results, expected around mid-November 2026. Liquidity and financing risk remain key considerations given the company's low market capitalization and ongoing losses. These observations are informational and do not constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for MTNB turns negative, indicating new downward trend
MTNB saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 84 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for MTNB turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTNB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MTNB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MTNB's RSI Indicator exited the oversold zone, 35 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTNB advanced for three days, in 160 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MTNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.648) is normal, around the industry mean (3.498). P/E Ratio (-1.035) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (34.843) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. MTNB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry Biotechnology